for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cumberland Pharmaceuticals, Inc.

CPIX.OQ

Latest Trade

5.57USD

Change

0.00(0.00%)

Volume

3,102

Today's Range

5.57

 - 

5.80

52 Week Range

4.73

 - 

7.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.57
Open
5.80
Volume
3,102
3M AVG Volume
0.71
Today's High
5.80
Today's Low
5.57
52 Week High
7.00
52 Week Low
4.73
Shares Out (MIL)
15.37
Market Cap (MIL)
87.17
Forward P/E
14.18
Dividend (Yield %)
--

Next Event

Q3 2019 Cumberland Pharmaceuticals Inc Earnings Release

Latest Developments

More

Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program

Cumberland Says FDA Informed Submission For Update To Caldolor Was Not Accepted For Review

Cumberland Pharmaceuticals Says FDA Sent Co Goal Extension Letter To Allow Additional Time To Review Application For Methotrexate Product Line

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Industry

Biotechnology & Drugs

Contact Info

2525 W End Ave Ste 950

+1.615.2550068

http://www.cumberlandpharma.com/

Executive Leadership

A. J. Kazimi

Chairman of the Board, Principal Executive Officer

Michael P Bonner

Senior Director Finance and Accounting and Chief Financial Officer

Martin E. Cearnal

Senior Vice President, Chief Commercial Officer, Director

Leo B Pavliv

Senior Vice President - Operations, Chief Development Officer

James L. Herman

Vice President - National Accounts, Chief Compliance Officer

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.030

2019(E)

0.400
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.92
Price To Book (MRQ)
1.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
37.00
LT Debt To Equity (MRQ)
37.00
Return on Investment (TTM)
-5.65
Return on Equity (TTM)
-4.55

Latest News

Latest News

BRIEF-Cumberland Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.09

* CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cumberland Pharmaceuticals Expands Into Oncology Support

* CUMBERLAND PHARMACEUTICALS EXPANDS INTO ONCOLOGY SUPPORT Source text for Eikon: Further company coverage:

BRIEF-Cumberland Pharmaceuticals- Entered Agreement With Gastro-Entero Logic To Acquire Assets Associated With Omeclamox((Reg))-Pak

* CUMBERLAND PHARMACEUTICALS-ON MARCH 13, ENTERED AGREEMENT WITH GASTRO-ENTERO LOGIC, LLC TO ACQUIRE ASSETS ASSOCIATED WITH OMECLAMOX -PAK

BRIEF-Cumberland Pharma Q4 Adjusted Earnings Per Share $0.03

* CUMBERLAND PHARMACEUTICALS REPORTS 25% REVENUE GROWTH FOR THE FULL YEAR 2017

BRIEF-Cumberland Pharma Says Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients

* CUMBERLAND PHARMACEUTICALS INC - NEWLY PUBLISHED DATA DEMONSTRATES AMIFOSTINE REDUCES GASTRO-INTESTINAL TOXICITY FOR MULTIPLE MYELOMA PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million

* Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million Source text: (http://bit.ly/2jazuqV) Further company coverage:

BRIEF-Cumberland Pharmaceutical reports Q3 loss per share $0.05

* Cumberland Pharmaceutical reports 27% revenue growth in the third quarter

BRIEF-Cumberland Pharmaceuticals launches promotion of Totect in U.S. for emergency oncology intervention

* Cumberland Pharmaceuticals launches promotion of Totect® in the U.S. for emergency oncology intervention

BRIEF-Cumberland Pharmaceuticals Q2 adjusted loss per share $0.05

* Cumberland Pharmaceutical reports double digit revenue growth for the fourth consecutive quarter

BRIEF-Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support

* Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support

BRIEF-Stonepine Capital Management reports 6.8 percent passive stake in Cumberland Pharmaceuticals

* Stonepine Capital Management Llc reports 6.8 percent passive stake in Cumberland Pharmaceuticals Inc as of May 9 - SEC filing Source text for Eikon: (http://bit.ly/2qA4bqN) Further company coverage:

BRIEF-Cumberland Pharmaceuticals reports q1 adjusted EPS $0.02

* Cumberland pharmaceuticals reports revenue growth of 25% in first quarter 2017

BRIEF-Cumberland Pharmaceuticals entered into a co-promotion partnership with Poly Pharmaceuticals for Kristalose within U.S.

* Cumberland Pharmaceuticals Inc - Entered into a co-promotion partnership with Poly Pharmaceuticals Inc for Kristalose within United States

BRIEF-Cumberland Pharmaceuticals says caldolor demonstrates significant post surgical pain reduction and decrease in opioid use

* Cumberland Pharmaceuticals Inc says Caldolor demonstrates significant post surgical pain reduction and decrease in opioid use Source text for Eikon: Further company coverage:

BRIEF-Cumberland Pharmaceuticals, Clinigen enter U.S. commercialization agreement for Totect

* Cumberland pharmaceuticals and Clinigen enter exclusive U.S. commercialization agreement for Totect

BRIEF-Cumberland Pharmaceuticals acquires U.S. rights to Nordic Group's methotrexate injection products

* Says it will register and commercialize methotrexate products in United States

BRIEF-Cumberland Pharmaceuticals Q3 earnings per share $0.01

* Cumberland Pharmaceuticals reports third quarter & year to date 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up